## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($55.33)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference**
- Source: Investing News Network | 20251223T140827 | Neutral | Relevance: 100%
- Bio-Techne Corporation (NASDAQ: TECH) announced that its President and CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on January 13, 2026, at 9:00 a.m. PST. A live webcast of the presentation will be available on the company's Investor Relations website. Bio-Techne is a global life sciences company that generated over $1.2 billion in net sales in fiscal 2025.

**2. Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference**
- Source: WBOY.com | 20251223T120842 | Neutral | Relevance: 100%
- Bio-Techne Corporation announced that its President and CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m. PST. A live webcast of the presentation will be available on the company's Investor Relations website. Bio-Techne is a global life sciences company providing tools and reagents for research and clinical diagnostics, with over $1.2 billion in net sales in fiscal 2025.

**3. Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference**
- Source: The AI Journal | 20251223T125041 | Neutral | Relevance: 100%
- Bio-Techne Corporation announced that its President and CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on January 13, 2026, at 9:00 a.m. PST. A live webcast of the presentation will be available on the company's Investor Relations website. Bio-Techne is a global life sciences company providing tools and reagents for research and diagnostics, with over $1.2 billion in net sales in fiscal 2025.

**4. Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference**
- Source: Nasdaq | 20251223T120907 | Neutral | Relevance: 100%
- Bio-Techne Corporation announced that its President and CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on January 13, 2026. A live webcast of the presentation will be available on the company's Investor Relations website. Bio-Techne is a global life sciences company that provides innovative tools and reagents for research and clinical diagnostics.

**5. Riverbridge Partners LLC Trims Stock Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251222T130159 | Neutral | Relevance: 99%
- Riverbridge Partners LLC reduced its stake in Bio-Techne Corp ($TECH) by 5.1% in Q3, now holding 906,442 shares valued at approximately $50.4 million. Despite missing revenue expectations, Bio-Techne reported Q3 EPS in line with estimates and maintains a "Moderate Buy" consensus from analysts with an average price target of $71. The company also announced a quarterly dividend of $0.08 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 27.3x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 27.3 |
| Current P/E | 30.0 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.0% to -3.5% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 47. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.53% (CS: 19) | Weak |
| RSI_14 | 47.4 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.972x | Below |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $59.25
- **Stop Loss:** $55.33 (6.6% risk)
- **Target:** $67.09 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 306
- **Position Value:** $18,130.50
- **Portfolio %:** 18.13%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*